We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
After Novartis eye care spinoff Alcon made a successful debut on the Swiss Exchange earlier this month, some analysts used it as an argument to make a bullish case for Bausch Health. But one analyst disagrees.